JJJia-Hao Jiang

Jia-Hao Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jia-Hao Jiang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Jianyong Ding

    Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    11 shared publications
  • Jian Gao

    Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China

    7 shared publications
  • Shuai Wang

    Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China

    6 shared publications
  • Yong-Qiang Ao

    Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China

    6 shared publications
  • Chun Jin

    Department of Thoracic Surgery, Changhai Hospital, Second Military Medical University (Naval Medical University), Shanghai, China

    4 shared publications
  • Hai-Kun Wang

    CAS Key Laboratory of Molecular Virology and Immunology, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Beijing, China

    4 shared publications

Latest Publications

  • Open Access

    Interferon-elicited lipoprotein metabolism in lung fibroblasts facilitates premetastatic niche formation

    by Jian Gao, Yilan Huang, Xiaojun Zhang, Chao Gao, Yiran Zhuang, Zheng Han, Mingyu Xia, Chun Jin, Dingguo Wang, Lingxian Zhang, et al.

    While premetastatic niche formation is known to affect primary tumors lung metastases, the role of lung stromal cells in this process remains unclear. Here, by performing multiomics sequencing, we identify interferon-regulated CD34+fibroblasts that reshape the immunosuppressive lung microenvironment via VLDLR-mediated lipoprotein metabolism activation. Increased lipoprotein uptake facilitates intracellular lipid accumulation, followed by CD155 expression in fibroblasts. CD155+fibroblasts strongly induce cytotoxic CD8+T and NK cell exhaustion, resulting in the formation of a premetastatic niche. The genetic disruption of the interferon–VLDLR–CD155 axis robustly reinstates immune surveillance and suppresses lung metastasis in multiple tumor models. Notably, interferon-based therapy is potentiated by specific silencing of the interferon response in fibroblasts or CD155 blockade. Moreover, the FTO-YTHDF2-mediated STAT1 m6A modification results in differences in the interferon response. Collectively, our findings reveal how interferon-induced metabolic rewiring in fibroblasts promotes metastatic competence via CD155-mediated immune evasion, suggesting stromal-targeted strategies for treating lung metastasis.


  • Open Access

    Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: a prospective, single-arm, phase II study

    by Shuai Wang, Xinyu Yang, Jiahao Jiang, Fei Liang, Yuansheng Zheng, Yongqiang Ao, Jian Gao, Hao Wang, Lijie Tan, Jianyong Ding

    Pleural spread or recurrence of thymic epithelial tumors (TETs) is a tricky puzzle in the clinic and there is currently no recognized effective treatment. This trial evaluated the safety and efficacy of cytoreductive surgery and hyperthermic intrathoracic chemotherapy (S-HITOC) for TETs with pleural spread or recurrence. Here, we reported short-term outcomes of enrolled 45 patients receiving S-HITOC with 25 mg/m2 doxorubicin and 50 mg/m2 cisplatin. The pleural tumor index (PTI) has been proposed for evaluating pleural tumor burden. Treatment-related adverse events of grade ≥3 occurred in eight (17.8%) patients. The pain Visual analog scale (VAS) score was 5.4 ± 1.9 on the 1st day after treatment and was similar to that at baseline level on the 7th day after treatment (p = 0.218). There was no significant difference in the quality of life score (p = 0.676) between baseline and the 60th day after treatment. The estimated 2-year PFS and OS rates were 82.8% and 100.0%, respectively. Subgroup analyses revealed that patients with PTI scores >10 had worse PFS than those with PTI scores ≤10 (p < 0.001). S-HITOC had a manageable complication rate. Early clinical outcomes confirmed that S-HITOC offers encouraging oncological benefits for TETs and satisfactory control of myasthenia gravis. Trial number: NCT05446935.


  • Open Access

    FHL2 activates β-catenin/Wnt signaling by complexing with APC and TRIM63 in lung adenocarcinoma

    by Jian Gao, Yong-Qiang Ao, Jie Deng, Miao Lin, Shuai Wang, Jia-Hao Jiang, Jian-Yong Ding


  • Open Access

    A new pragmatic classification system for thymoma-associated myasthenia gravis: a retrospective cohort study

    by Yongqiang Ao, Jiahao Jiang, Junjie Miao, Jian Gao, Xinyu Yang, Yuansheng Zheng, Fei Liang, Shuai Wang, Jihong Dong, Jianyong Ding

    The management and outcomes of patients with thymoma-associated myasthenia gravis (TAMG) are heterogeneous. Here, the authors propose a novel classification system based on Masaoka stage and Myasthenia Gravis Foundation of America (MGFA) classification, aiming to guide surgical decisions and perioperative management for these patients. Considering both oncological and neurological factors, this novel TAMG classification provides valuable information on outcome stratification and clinical decision-making for TAMG.


  • Open Access

    ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3

    by Yong-Qiang Ao, Jian Gao, Chun Jin, Shuai Wang, Li-Cheng Zhang, Jie Deng, Zong-Wei Chen, Hai-Kun Wang, Jia-Hao Jiang, Jian-Yong Ding

    Background: Activating signal cointegrator 3 (ASCC3) has been identified as an oncogenic factor that impairs host immune defense. However, the underlying mechanisms of carcinogenesis and its impact on the antitumor immune response remain unclear. In this study, we aimed to investigate the molecular mechanisms of ASCC3 in the progression of non-small cell lung cancer (NSCLC). Methods: Single-cell sequencing data from the Gene Expression Omnibus and gene expression profiles from The Cancer Genome Atlas database were analyzed. The expression, clinical relevance and biological functions of ASCC3 in NSCLC were explored. Then, RNA sequencing, immunoprecipitation, mass spectrometry, immunofluorescence, and flow cytometry analyses were conducted to explore the underlying molecular mechanisms. In addition, in vivo experiments in mouse models were conducted to explore the probability of ASCC3 knockdown to improve the efficacy of anti-Programmed Death-1 (PD-1) therapy in NSCLC. Results: ASCC3 was significantly upregulated in NSCLC and correlated with poor pathological characteristics and prognosis in patients with NSCLC. Overexpression of ASCC3 promoted malignant phenotypes of NSCLC cells and induced an immunosuppressive tumor microenvironment, which was characterized by a decrease in CD8+ T cells, natural killer cells and dendritic cells but an increase in regulatory T(Treg) cells. Mechanistically, ASCC3 stabilized signal transducer and activator of transcription (STAT)3 signaling by recruiting Cullin-associated and neddylation dissociated 1 (CAND1), which inhibited ubiquitin-mediated degradation of STAT3, thereby impairing the type I interferon response of tumor cells and promoting the immunosuppression and progression of NSCLC. Furthermore, high expression of ASCC3 impaired the efficacy of anti-PD-1 therapy, and an anti-PD-1 antibody combined with ASCC3 knockdown exerted promising synergistic efficacy in a preclinical mouse model. Conclusion: ASCC3 could stabilize the STAT3 pathway via CAND1, reshaping the tumor microenvironment and inducing resistance to anti-PD-1 therapy, which promotes the progression of NSCLC. It is a reliable prognostic indicator and can be a target in combination therapy for NSCLC.


  • WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors

    by Jian Gao, Yongqiang Ao, Shuai Wang, Zongwei Chen, Yi Zhang, Jianyong Ding, Jiahao Jiang


  • Open Access

    Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer

    by Yong-Qiang Ao, Jian Gao, Ling-Xian Zhang, Jie Deng, Shuai Wang, Miao Lin, Hai-Kun Wang, Jian-Yong Ding, Jia-Hao Jiang

    Background: The scavenger receptor CD36 was reported to be highly expressed on tumor-infiltrating CD8+ T cells, but the clinical role remains obscure. This study aims to explore the infiltration and clinical value of CD36+CD8+ T cells in NSCLC. Methods: Immunohistochemistry and immunofluorescence were conducted for survival analyses and immunological evaluation in 232 NSCLC patients in Zhongshan Hospital. Flow cytometry analyses were carried out to assess the immune cells from fresh tumor samples, non-tumor tissues and peripheral blood. In vitro tumor infiltrating lymphocytes cultures were conducted to test the effect of CD36 blockage. Results: Accumulation of CD36+CD8+ T cells in tumor tissues was correlated with more advanced stage (p < 0.001), larger tumor size (p < 0.01), and lymph node metastasis (p < 0.0001) in NSCLC. Moreover, high infiltration of CD36+CD8+ T cells indicated poor prognosis in terms of both overall survival (OS) and recurrence-free survival (RFS) and inferior chemotherapy response. CD36+CD8+ T cells showed decreased GZMB (p < 0.0001) and IFN-γ (p < 0.001) with elevated PD-1 (p < 0.0001) and TIGIT (p < 0.0001). Analysis of tumor-infiltrating immune cell landscape revealed a positive correlation between CD36+CD8+ T cells and Tregs (p < 0.01) and M2-polarized macrophages (p < 0.01) but a negative correlation with Th1 (p < 0.05). Notably, inhibition of CD36 partially restored the cytotoxic function of CD8+ T cells by producing more GZMB and IFN-γ. Conclusion: CD36+CD8+ T cells exhibit impaired immune function and high infiltration of CD36+CD8+ T cells indicated poor prognosis and inferior chemotherapy response in NSCLC patients. CD36 could be a therapeutic target in combination with chemotherapy in NSCLC patients.


  • Open Access

    Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1

    by Jian Gao, Yong-Qiang Ao, Ling-Xian Zhang, Jie Deng, Shuai Wang, Hai-Kun Wang, Jia-Hao Jiang, Jian-Yong Ding

    Background: Although success was achieved in the therapy for a minority of advanced lung adenocarcinoma (LUAD) patients, anti-programmed death 1 (PD1) resistance was found in most LUAD patients. Here, we aimed to uncover a potential role of exosomal circular RNAs (circRNAs) in LUAD refractory to PD1 blockade. Methods: circRNA sequencing and qRT-PCR were performed to determine the level of exosomal circRNAs in LUAD patients subsequently treated with anti-PD1. Then, the RNA pulldown, RNA immunoprecipitation, mass spectrometry, chromatin immunoprecipitation, luciferase reporter assays, flow cytometry, RNA sequencing, and in vitro and in vivo models were used to uncover the biological functions and underlying mechanism of circZNF451 in LUAD anti-PD1 treatment resistance. Results: circRNA sequencing and qRT-PCR identified the up-regulation of exosomal circZNF451 from LUAD patients with progressive disease (PD) compared to those with partial remission (PR) after PD1 blockade therapy. Furthermore, elevated circZNF451 was revealed to be associated with poor prognosis of LUAD patients. Additionally, exosomal circZNF451 was demonstrated to induce an anti-inflammatory phenotype in macrophages and exhaustion of cytotoxic CD8+ T cells, and enhanced TRIM56-mediated degradation of FXR1 to activate the ELF4–IRF4 pathway in macrophages. By transgenic mice, knockout of ELF4 in macrophages was found to rescue immunotherapy efficacy in tumors with high level of exosomal circZNF451. Conclusion: Exosomal circZNF451 reshapes the tumor immune microenvironment by inducing macrophages polarization via the FXR1- ELF4–IRF4 axis and is a novel biomarker for predicting the sensitivity of PD1 blockade in LUAD.